RAPS Taiwan Chapter Becomes First in Asia - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
RAPS Taiwan Chapter Becomes First in Asia

Source: Company News Release

The Regulatory Affairs Professionals Society (RAPS) has announced the establishment of a new chapter in Taiwan, its first in Asia. The RAPS Taiwan Chapter originated as an affiliate. In making the move to become an official chapter, it will be able to offer additional resources and opportunities to the regulatory community in Taiwan.

“Regulatory professionals from Taiwan can look forward to local training and networking activities while continuing to access RAPS resources for their professional development and career progression,” said RAPS Executive Director Sherry Keramidas, PhD, FASAE, CAE.

The chapter is the latest in a series of steps expanding RAPS’ presence in Asia. Last year, RAPS opened two new offices in Asia—a Pan-Asia office in Singapore, serving the entire Asia-Pacific region, and another in Shanghai, serving the regulatory community in China—and also began working with the government of Singapore to develop and implement a new medical device regulatory affairs training program there.

Taiwan Chapter membership is open to all who reside in Taiwan and are involved in regulatory affairs, quality or other functions related to healthcare product regulation. The chapter has a web page in Mandarin Chinese as well as a Facebook page. For information about how to join and membership benefits, contact the RAPS Taiwan Chapter via the web page at http://www.raps-in-taiwan.org.tw.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Company News Release,
Click here